A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid.

作者: Meagan B. Myers , Karen L. McKim , Barbara L. Parsons

DOI: 10.1002/MC.21953

关键词:

摘要: The molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely attributed to chromosomal rearrangements and point mutations in genes within the MAPK pathway (i.e., BRAF RAS). Despite KRAS being 6th most frequently mutated gene for all cancers, reported frequency cancer only 2%. This may be due, part, use insensitive mutation detection methods such as DNA sequencing. Therefore, using sensitive quantitative ACB-PCR approach, we quantified codon 12 GGT  GAT GGT  GTT mutant fraction (MF) 20 normal tissues, 17 primary PTC, 2 metastatic 1 anaplastic carcinoma. We observed measurable levels GAT or GTT tissues. For PTCs, 29.4% 35.3% had MF above 95% upper confidence interval corresponding MFs thyroid. highest were associated with tumors follicular characteristics relatively high tumor necrosis. results indicate subpopulations are present a large number tumors, fact previously unrecognized. presence an aggressive phenotype, thus directing course clinical treatment. © 2012 Wiley Periodicals, Inc.

参考文章(35)
David Hiltzik, Diane L. Carlson, R. Michael Tuttle, Shaokun Chuai, Nicole Ishill, Ashok Shaha, Jatin P. Shah, Buvanesh Singh, Ronald A. Ghossein, Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer. ,vol. 106, pp. 1286- 1295 ,(2006) , 10.1002/CNCR.21739
Maela Del Grammastro, Mariagrazia Sciarrotta, Sara Malatesta, Carmen Nuzzo, Giovanna Finocchiaro, Bruno Perrucci, Donatella Carlone, Alain J. Gelibter, Anna Ceribelli, Andrea Mezzetti, Stefano Iacobelli, Francesco Cognetti, Fiamma Buttitta, Antonio Marchetti, Michele Milella, Lara Felicioni, Federico Cappuzzo, Luciana Irtelli, Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones Neoplasia. ,vol. 11, pp. 1084- 1092 ,(2009) , 10.1593/NEO.09814
Edna T Kimura, Marina N Nikiforova, Zhaowen Zhu, Jeffrey A Knauf, Yuri E Nikiforov, James A Fagin, None, High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research. ,vol. 63, pp. 1454- 1457 ,(2003)
Fahd Al-Mulla, Elaine M. MacKenzie, Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. The Journal of Pathology. ,vol. 195, pp. 549- 556 ,(2001) , 10.1002/PATH.995
Matteo Landriscina, Giuseppe Pannone, Annamaria Piscazzi, Paolo Toti, Annarita Fabiano, Simona Tortorella, Rossella Occhini, Antonio Ambrosi, Pantaleo Bufo, Mauro Cignarelli, Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans. Thyroid. ,vol. 21, pp. 1227- 1234 ,(2011) , 10.1089/THY.2011.0172
Michael Rivera, Ronald A. Ghossein, Heiko Schoder, Daniel Gomez, Steven M. Larson, R. Michael Tuttle, Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma Cancer. ,vol. 113, pp. 48- 56 ,(2008) , 10.1002/CNCR.23515
Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag, Kevan M. Shokat, Neal Rosen, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature. ,vol. 464, pp. 427- 430 ,(2010) , 10.1038/NATURE08902
Page B. McKinzie, Barbara L. Parsons, Detection of rare K-ras codon 12 mutations using allele-specific competitive blocker PCR. Mutation Research-genetic Toxicology and Environmental Mutagenesis. ,vol. 517, pp. 209- 220 ,(2002) , 10.1016/S1383-5718(02)00077-3